Corcept Therapeutics Incorporated (CORT) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Menlo Park, CA, United States. Der aktuelle CEO ist Joseph K. Belanoff.
CORT hat IPO-Datum 2004-04-14, 500 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $4.65B.
Corcept Therapeutics Incorporated is a biopharmaceutical company headquartered in Menlo Park, California, specializing in the discovery, development, and commercialization of drugs for severe metabolic, oncologic, and neuropsychiatric disorders. The company markets Korlym (mifepristone), an oral medication for treating hyperglycemia in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and are unsuitable for or have failed surgery. Corcept's pipeline includes relacorilant for Cushing's syndrome treatment, a combination therapy of nab-paclitaxel with relacorilant currently in Phase II trials for advanced ovarian tumors, and selective cortisol modulators targeting conditions such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain. Founded in 1998, the company leverages its expertise in cortisol modulation to address unmet medical needs across multiple therapeutic areas.
